Lifeward (NASDAQ:LFWD – Get Free Report) had its price objective decreased by stock analysts at HC Wainwright from $10.00 to $8.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s price target indicates a potential upside of 97.04% from the stock’s previous close.
A number of other research analysts have also recently weighed in on LFWD. Zacks Research upgraded Lifeward from a “strong sell” rating to a “hold” rating in a research report on Monday, July 27th. Weiss Ratings lowered shares of Lifeward from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Finally, Citigroup reiterated a “buy” rating on shares of Lifeward in a research report on Friday, August 21st. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Lifeward presently has a consensus rating of “Hold” and a consensus price target of $8.00.
Check Out Our Latest Stock Analysis on Lifeward
Lifeward Stock Performance
Shares of LFWD stock opened at $4.06 on Monday. The stock has a fifty day moving average price of $6.35 and a 200 day moving average price of $6.85. The stock has a market cap of $11.49 million, a PE ratio of -0.26 and a beta of 0.55. Lifeward has a 1 year low of $3.81 and a 1 year high of $9.61. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.77 and a current ratio of 2.33.
Lifeward (NASDAQ:LFWD – Get Free Report) last posted its earnings results on Saturday, August 15th. The company reported ($1.46) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.07). The firm had revenue of $6.62 million for the quarter, compared to analysts’ expectations of $6.53 million. Lifeward had a negative return on equity of 281.70% and a negative net margin of 155.37%. Sell-side analysts forecast that Lifeward will post -0.44 earnings per share for the current fiscal year.
Lifeward Company Profile
Lifeward Ltd. develops and markets medical devices for mobility, rehabilitation and physical therapy. Its products include wearable robotic exoskeletons designed to help people with mobility impairments stand and walk, as well as systems used in rehabilitation settings. The company’s offerings include the ReWalk exoskeleton for people with spinal cord injuries and the ReStore exo-suit for gait training after stroke. Lifeward also sells AlterG anti-gravity treadmills, which use differential air pressure to reduce the user’s effective body weight during walking or running exercises.
See Also
- Five stocks we like better than Lifeward
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Lifeward Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifeward and related companies with MarketBeat.com's FREE daily email newsletter.
